Center for Research on Behavioral Health and Human Services Delivery, University of Georgia, Athens, GA 30602-2401, USA.
J Subst Abuse Treat. 2010 Apr;38(3):275-83. doi: 10.1016/j.jsat.2010.01.003. Epub 2010 Feb 1.
Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's Clinical Trials Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a 2-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.
组织参与临床研究可能导致治疗机构采用干预措施，但目前尚不清楚研究参与是否会在测试的具体干预措施之外增强创新性。国家药物滥用研究所的临床试验网络（CTN）是一个考虑这个研究问题的平台。迄今为止，CTN 尚未开展酒精使用障碍（AUD）药物治疗的研究，因此，CTN 附属项目对创新 AUD 药物治疗的更多采用表明研究网络参与具有附加价值。我们使用来自 CTN 和非 CTN 公共资助治疗项目的 pooled sample 的纵向数据，在 2 年的时间内研究了纳曲酮片和安非他酮的采用情况。在控制了一系列组织特征的影响后，CTN 附属项目在 24 个月的随访中更有可能采用纳曲酮片和安非他酮。因此，研究网络参与可能会增强组织的创新性，包括网络范围之外的干预措施。
